Literature DB >> 32502097

Angiotensin-converting enzyme inhibitors, angiotensin II type 1 receptor blockers and risk of COVID 19: information from Bartter's and Gitelman's syndromes patients.

Lorenzo A Calò1, Paul A Davis2, Matteo Rigato1, Luca Sgarabotto1.   

Abstract

Entities:  

Year:  2020        PMID： 32502097     DOI： 10.1097/HJH.0000000000002495

Source DB:  PubMed          Journal:  J Hypertens        ISSN： 0263-6352            Impact factor:   4.844


× No keyword cloud information.
  4 in total

1.  Rho kinase inhibitors for SARS-CoV-2 induced acute respiratory distress syndrome: Support from Bartter's and Gitelman's syndrome patients.

Authors:  Lorenzo A Calò; Giovanni Bertoldi; Paul A Davis
Journal:  Pharmacol Res       Date:  2020-05-13       Impact factor: 7.658

2.  Risk prediction of COVID-19 incidence and mortality in a large multi-national hemodialysis cohort: implications for management of the pandemic in outpatient hemodialysis settings.

Authors:  Mathias Haarhaus; Carla Santos; Michael Haase; Pedro Mota Veiga; Carlos Lucas; Fernando Macario
Journal:  Clin Kidney J       Date:  2021-02-05

Review 3.  Are the Clinical Presentations (Phenotypes) of Gitelman's and Bartter's Syndromes Gene Mutations Driven by Their Effects on Intracellular pH, Their "pH" Enotype?

Authors:  Lorenzo A Calò; Paul A Davis
Journal:  Int J Mol Sci       Date:  2020-08-07       Impact factor: 5.923

4.  ACE2 and prognosis of COVID-19: Insights from Bartter's and Gitelman's syndromes patients.

Authors:  Lorenzo A Calò; Paul A Davis; Matteo Rigato; Luca Sgarabotto
Journal:  J Med Virol       Date:  2020-07-11       Impact factor: 20.693
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.